The effects of anti-depressants on depression symptom scores at 12 months follow-up in patients with cardiometabolic disease: results from a large primary care cohort

Bhautesh Dinesh Jani, David Purves, Sarah J.E. Barry, Colin Mccowan, Jonathan Cavanagh, Frances S. Mair

Research output: Contribution to journalArticle

Abstract

Background: Evidence on the long-term usefulness of anti-depressants in managing depression in cardiometabolic disease is limited. Aim: We examined the effects of anti-depressant prescribing on depressive symptoms at 12 months follow-up in patients with cardiometabolic disease and a positive depression screening result at baseline. Design and setting: We retrospectively reviewed routine UK primary care data for patients with coronary heart disease, diabetes and previous stroke for the year 2008-2009. 35,537 patients with one of the three above diseases underwent depression screening using the Hospital Anxiety and Depression Scale (HADS-D). Of 7080 patients with a positive screening result (HADS-D ? 8), 3933 (55.5 patients had a repeat HADS-D recorded at 12 months follow-up. Methods: We compared the change in HADS-D at follow-up and remission rate in those who were prescribed anti-depressants (n = 223) against those who were not (n = 3710). Results: The mean change in HADS-D from baseline, for the nonprescribed group was similar to the reduction observed in patients who were continuously prescribed (n = 93) with anti-depressants during follow-up. Patients who were prescribed intermittently (n = 72) or only one (n = 58) prescription during follow-up had a lower reduction in HADS-D compared to the nonprescribed group. There was no difference in remission rates between continuously prescribed and the nonprescribed group, but remission was lower in patients prescribed intermittently and single prescription. Conclusion: Improvement in depressive symptoms in patients with cardiometabolic disease at 12 months was not any better in patients prescribed with anti-depressants compared to the nonprescribed group. The role of anti-depressants in the management of depression in cardiometabolic disease merits further investigation.
LanguageEnglish
Pages373-379
Number of pages7
JournalJournal of Family Medicine and Primary Care
Volume4
Issue number3
DOIs
Publication statusPublished - 23 Jul 2015

Fingerprint

Primary Health Care
Depression
Prescriptions
Coronary Disease
4-amino-4'-hydroxylaminodiphenylsulfone
Anxiety
Stroke

Keywords

  • anti-depressants' effectiveness
  • coronary heart disease
  • depression
  • cardio-metabolic health
  • diabetes
  • primary care
  • stroke

Cite this

@article{51b85d2310644beda40de85a0eb38283,
title = "The effects of anti-depressants on depression symptom scores at 12 months follow-up in patients with cardiometabolic disease: results from a large primary care cohort",
abstract = "Background: Evidence on the long-term usefulness of anti-depressants in managing depression in cardiometabolic disease is limited. Aim: We examined the effects of anti-depressant prescribing on depressive symptoms at 12 months follow-up in patients with cardiometabolic disease and a positive depression screening result at baseline. Design and setting: We retrospectively reviewed routine UK primary care data for patients with coronary heart disease, diabetes and previous stroke for the year 2008-2009. 35,537 patients with one of the three above diseases underwent depression screening using the Hospital Anxiety and Depression Scale (HADS-D). Of 7080 patients with a positive screening result (HADS-D ? 8), 3933 (55.5 patients had a repeat HADS-D recorded at 12 months follow-up. Methods: We compared the change in HADS-D at follow-up and remission rate in those who were prescribed anti-depressants (n = 223) against those who were not (n = 3710). Results: The mean change in HADS-D from baseline, for the nonprescribed group was similar to the reduction observed in patients who were continuously prescribed (n = 93) with anti-depressants during follow-up. Patients who were prescribed intermittently (n = 72) or only one (n = 58) prescription during follow-up had a lower reduction in HADS-D compared to the nonprescribed group. There was no difference in remission rates between continuously prescribed and the nonprescribed group, but remission was lower in patients prescribed intermittently and single prescription. Conclusion: Improvement in depressive symptoms in patients with cardiometabolic disease at 12 months was not any better in patients prescribed with anti-depressants compared to the nonprescribed group. The role of anti-depressants in the management of depression in cardiometabolic disease merits further investigation.",
keywords = "anti-depressants' effectiveness, coronary heart disease, depression, cardio-metabolic health, diabetes, primary care, stroke",
author = "Jani, {Bhautesh Dinesh} and David Purves and Barry, {Sarah J.E.} and Colin Mccowan and Jonathan Cavanagh and Mair, {Frances S.}",
year = "2015",
month = "7",
day = "23",
doi = "10.4103/2249-4863.161324",
language = "English",
volume = "4",
pages = "373--379",
journal = "Journal of Family Medicine and Primary Care",
issn = "2249-4863",
number = "3",

}

The effects of anti-depressants on depression symptom scores at 12 months follow-up in patients with cardiometabolic disease : results from a large primary care cohort. / Jani, Bhautesh Dinesh; Purves, David; Barry, Sarah J.E.; Mccowan, Colin; Cavanagh, Jonathan; Mair, Frances S.

In: Journal of Family Medicine and Primary Care, Vol. 4, No. 3, 23.07.2015, p. 373-379.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effects of anti-depressants on depression symptom scores at 12 months follow-up in patients with cardiometabolic disease

T2 - Journal of Family Medicine and Primary Care

AU - Jani, Bhautesh Dinesh

AU - Purves, David

AU - Barry, Sarah J.E.

AU - Mccowan, Colin

AU - Cavanagh, Jonathan

AU - Mair, Frances S.

PY - 2015/7/23

Y1 - 2015/7/23

N2 - Background: Evidence on the long-term usefulness of anti-depressants in managing depression in cardiometabolic disease is limited. Aim: We examined the effects of anti-depressant prescribing on depressive symptoms at 12 months follow-up in patients with cardiometabolic disease and a positive depression screening result at baseline. Design and setting: We retrospectively reviewed routine UK primary care data for patients with coronary heart disease, diabetes and previous stroke for the year 2008-2009. 35,537 patients with one of the three above diseases underwent depression screening using the Hospital Anxiety and Depression Scale (HADS-D). Of 7080 patients with a positive screening result (HADS-D ? 8), 3933 (55.5 patients had a repeat HADS-D recorded at 12 months follow-up. Methods: We compared the change in HADS-D at follow-up and remission rate in those who were prescribed anti-depressants (n = 223) against those who were not (n = 3710). Results: The mean change in HADS-D from baseline, for the nonprescribed group was similar to the reduction observed in patients who were continuously prescribed (n = 93) with anti-depressants during follow-up. Patients who were prescribed intermittently (n = 72) or only one (n = 58) prescription during follow-up had a lower reduction in HADS-D compared to the nonprescribed group. There was no difference in remission rates between continuously prescribed and the nonprescribed group, but remission was lower in patients prescribed intermittently and single prescription. Conclusion: Improvement in depressive symptoms in patients with cardiometabolic disease at 12 months was not any better in patients prescribed with anti-depressants compared to the nonprescribed group. The role of anti-depressants in the management of depression in cardiometabolic disease merits further investigation.

AB - Background: Evidence on the long-term usefulness of anti-depressants in managing depression in cardiometabolic disease is limited. Aim: We examined the effects of anti-depressant prescribing on depressive symptoms at 12 months follow-up in patients with cardiometabolic disease and a positive depression screening result at baseline. Design and setting: We retrospectively reviewed routine UK primary care data for patients with coronary heart disease, diabetes and previous stroke for the year 2008-2009. 35,537 patients with one of the three above diseases underwent depression screening using the Hospital Anxiety and Depression Scale (HADS-D). Of 7080 patients with a positive screening result (HADS-D ? 8), 3933 (55.5 patients had a repeat HADS-D recorded at 12 months follow-up. Methods: We compared the change in HADS-D at follow-up and remission rate in those who were prescribed anti-depressants (n = 223) against those who were not (n = 3710). Results: The mean change in HADS-D from baseline, for the nonprescribed group was similar to the reduction observed in patients who were continuously prescribed (n = 93) with anti-depressants during follow-up. Patients who were prescribed intermittently (n = 72) or only one (n = 58) prescription during follow-up had a lower reduction in HADS-D compared to the nonprescribed group. There was no difference in remission rates between continuously prescribed and the nonprescribed group, but remission was lower in patients prescribed intermittently and single prescription. Conclusion: Improvement in depressive symptoms in patients with cardiometabolic disease at 12 months was not any better in patients prescribed with anti-depressants compared to the nonprescribed group. The role of anti-depressants in the management of depression in cardiometabolic disease merits further investigation.

KW - anti-depressants' effectiveness

KW - coronary heart disease

KW - depression

KW - cardio-metabolic health

KW - diabetes

KW - primary care

KW - stroke

UR - http://eprints.gla.ac.uk/108236/

U2 - 10.4103/2249-4863.161324

DO - 10.4103/2249-4863.161324

M3 - Article

VL - 4

SP - 373

EP - 379

JO - Journal of Family Medicine and Primary Care

JF - Journal of Family Medicine and Primary Care

SN - 2249-4863

IS - 3

ER -